Echo IQ Company Description

Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia.

It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure.

The company has a research collaboration with Mayo Clinic to evaluate echo IQ's proprietary artificial intelligence platform for cardiac risk stratification in oncology patients.

The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021.

Echo IQ Limited is headquartered in Sydney, Australia.

Echo IQ Limited

Country	Australia
Industry	Health Information Services
Sector	Healthcare
CEO	Dustin Haines

Contact Details

Address: 66 Clarence Street Sydney, NSW 2000 Australia
Phone	61 2 9159 3719
Website	echoiq.ai

Stock Details

Ticker Symbol	EIQ
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000195430
SIC Code	7372

Key Executives

Name	Position
Dustin Haines	Chief Executive Officer
Andrew Richard Grover	Executive Chairman
Nianh Byrne	Finance Manager
Patrick O'Shea	Head of Strategy and Operations
Sam Dribin	Chief Technology Officer
Prof. David Playford	Chief Medical Advisor
Donald L. Fowler	President of Echo IQ USA
Deon Strydom	Chief Commercial Officer
Prof. Geoffrey A. Strange	Chief Research and Strategy Officer
Dane Brescacin	SVice President of Regulatory Affairs